The paper detail the development and testing of engineered immunosuppressive and fibrosis-targeted dendritic cells (iCDCs) as a novel treatment for heart failure. These specialized cells are designed to home specifically to damaged heart tissue by targeting fibroblast activation protein (FAP), where they deliver a combination of immunomodulatory factors including IL-10, CTLA4-Ig, and PD-L1. Experimental results in mouse and non-human primate models show that this therapy effectively reduces pathological cardiac fibrosis, enhances blood flow, and preserves heart muscle contractility after injury. Mechanistically, the iCDCs work by suppressing harmful inflammatory responses and promoting the growth of regulatory T cells that aid in tissue repair. This research suggests that localized immune reprogramming via dendritic cells can provide long-lasting cardioprotection without causing systemic toxicity. Ultimately, the study positions iCDCs as a sophisticated therapeutic platform for managing chronic heart conditions and preventing maladaptive cardiac remodelling.

References:

• Li X, Li J, Li G, et al. Engineered immunosuppressive dendritic cells protect against cardiac remodelling[J]. Nature, 2026: 1-11.